Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

clinical trial

Details

Instance of: clinical trial
Start time: 21 October 2019
End time: February 2022
Country: United States
Main subject: edaravone, amyotrophic lateral sclerosis, motor neuron disease
contributor to the creative work or subject: Massachusetts General Hospital
minimum age: 18
number of participants: 300
research intervention: edaravone
study type: observational study
title: Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Nothing in the MetaHistoryBook collection references this item yet.